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Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by an 
abnormal and chronic inflammatory response in the lung that underlies the chronic airflow 
obstruction of the small airways, the inexorable decline of lung function, and the severity 
of the disease. The control of this inflammation remains a key strategy for treating the 
disease; however, there are no current anti-inflammatory treatments that are effective. 
Although glucocorticoids (GCs) effectively control inflammation in many diseases such 
as asthma, they are less effective in COPD. The molecular mechanisms that contribute 
to the development of this relative GC-insensitive inflammation in the lung of patients 
with COPD remain unclear. However, recent studies have indicated novel mechanisms 
and possible therapeutic strategies. One of the major mechanisms proposed is an oxidant-
mediated alteration in the signaling pathways in the inflammatory cells in the lung, which 
may result in the impairment of repressor proteins used by the GC receptor to inhibit the 
transcription of proinflammatory genes. Although these studies have described mechanisms 
and targets by which GC function can be restored in cells from patients with COPD, more 
work is needed to completely elucidate these and other pathways that may be involved in 
order to allow for more confident therapeutic targeting. Given the relative GC-insensitive 
nature of the inflammation in COPD, a combination of therapies in addition to a restoration 
of GC function, including effective alternative anti-inflammatory targets, antioxidants, and 
proresolving therapeutic strategies, is likely to provide better targeting and improvement in 
the management of the disease.
Keywords: inflammation, oxidative stress, histone deacetylase, phosphoinositol 3-kinase, p38 
mitogen-activated protein kinase
Definition and prevalence
Chronic obstructive pulmonary disease (COPD) is a disease of the lungs where there 
is an abnormal chronic inflammatory response.1 This is associated with remodeling 
and narrowing of the small airways, which results in airflow limitation and a gradual 
inexorable decline of lung function that is not fully reversible and is progressive.2,3 
COPD is usually diagnosed in the clinic by a postbronchodilator forced expiratory 
volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of ,70% and a FEV1 
of $80% predicted.3,4 According to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines, COPD severity can be categorized into 4 stages (I–IV) 
on the basis of FEV1 (Table 1).3 COPD is considered a preventable and treatable 
disease in which there may be some significant extrapulmonary effects that may also 
contribute to the severity of the disease in individual patients.3
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The abnormal inflammatory response in the lungs of 
patients with COPD is usually considered to be the result 
associated with exposure to noxious particles or gases such as 
those contained in cigarette smoke, which is  recognized as the 
main etiological factor associated with the development of 
COPD.1,4 However, cigarette smoking does not fully explain 
variations in disease prevalence; therefore, other risk factors 
are likely to be involved, such as exposure to fossil fuels and 
environmental traffic pollution.5 One of the important fea-
tures of the disease is that the chronic inflammatory response 
in the lung often persists even when the main exogenous 
driving factor such as cigarette smoke has been removed. 
This apparent self-perpetuation of the chronic inflammatory 
response may contribute to the continuous decline of lung 
function and subsequent progression of the disease.1,6,7
COPD is a leading cause of morbidity and mortality. 
Although the incidence of cigarette smoking in the western 
world is decreasing, as the population ages, the incidence 
of COPD is likely to increase before decreasing given the 
latent nature of the disease. Furthermore, cigarette smoking 
is increasing in densely populated developing nations such 
as China, which will further enhance the global burden 
of the disease. The World Health Organization (WHO) 
 estimated that 3 million people died of COPD in 2005, and 
there were approximately 210 million people with COPD 
in 2007.8  Currently, COPD is the fifth most common cause 
of mortality worldwide, but total deaths due to the disease 
are predicted to rise by 30% in the next 10 years.8 COPD 
is now predicted to become the third leading cause of death 
worldwide by around 2030.8
Pathophysiology
COPD is a complex disease and is often used as an “umbrella” 
term to incorporate 3 distinct disease processes, chronic 
 bronchitis, emphysema, and small airways disease, which 
may be present in varying degrees and contribute to the 
 airflow obstruction.1 It is worth noting that chronic  bronchitis 
is usually defined by the symptoms of cough and sputum 
 production over the winter months, and this usually may or 
may not be associated with any indices of airflow  obstruction. 
The increased mucus production due to  submucosal 
gland hypertrophy and hyperplasia in chronic bronchitis 
coupled with the reduction in mucociliary  clearance seen 
in patients with COPD is a major contributing factor in 
bacterial  colonization and infections, which contributes to 
exacerbations.1,9,10 The destruction of the parenchyma and 
enlargement of the alveoli and alveolar ducts distal to the 
terminal bronchioles termed “emphysema” are likely to 
contribute to airflow limitation because of a loss of the lung 
elastic recoil.11 The degree of airflow limitation (as measured 
by FEV1) is correlated with the degree of wall thickening 
of the small airways, providing evidence of a role for small 
airway remodeling in the airflow obstruction in COPD.2 
The decline of lung function and the severity of the disease 
correlated with the degree of narrowing of the small airways 
but not with the degree of emphysema or chronic bronchitis 
present.2 This suggests that the narrowing of the small airway 
may be a predominant factor in the development of airflow 
limitation in COPD.
The degree of inflammation in the lungs of patients with 
COPD increases with the severity of the disease.2 The inflam-
mation is characterized by an accumulation of neutrophils, 
macrophages, B cells, lymphoid aggregates, and CD8+ T cells, 
particularly in the small airways.1,6,12 This is likely to represent 
both innate and adaptive immune responses to the toxic particles 
and gases.13 This inflammation is orchestrated by a complex 
milieu of proinflammatory mediators, including chemokines, 
such as CCL2, CXCL1, and CXCL8 (11); cytokines, such as 
tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and 
interferon (IFN)-γ; and proteases, such as neutrophil elastase 
and metalloproteinase-9.7 As the severity of COPD advances, 
there is an increase in the numbers of B cells, which may 
indicate an adaptive immune component to the inflammatory 
response in the later stages of COPD.2,14 Autoimmunity may 
also play a role in COPD, in particular, caused by cigarette 
smoke-damaged proteins, with autoantibodies, including anti-
elastin, antiepithelial, and tobacco anti-idiotypic antibodies, 
detected in smoking patients with COPD.15–17
Table 1 GOLD stages of chronic obstructive pulmonary disease 
severity
COPD  
severity
Characteristics
FEV1/ 
FVC
FEV1
GOLD Stage I 
(mild)
,70% –
GOLD Stage II 
(moderate)
,70% ,50%–70%
GOLD Stage III 
(severe)
,70% ,30%–50%
GOLD Stage Iv 
(very severe)
,70% ,30% or ,30%–50% with respiratory 
insufficiency (defined as PaO2 , 60 mmHg 
and/or PCO2 , 50 mmHg while breathing 
air at sea level)
Abbreviations: GOLD, global initiative for chronic obstructive lung disease; 
COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in 
1 sec; FvC, forced vital capacity; PaO2, partial pressure of oxygen in arterial blood; 
PCO2, partial pressure of carbon dioxide.
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Some inflammatory cells also appear to be  functionally 
altered in COPD, which is likely to contribute to the patho-
genesis and progression of the disease. In particular, the 
phagocytic ability of both neutrophils and macrophages 
is reduced, which is likely to contribute to the ineffective 
control of bacterial colonization and clearance of dead cells, 
respectively.18–20 Impairment in the clearance of dead and 
damaged cells is also likely to contribute to the enhancement 
and chronic nature of the inflammatory response.
Glucocorticoid treatment in COPD
The abnormal chronic inflammation in the lung of patients 
with COPD is widely recognized as a prominent driving 
force in the progression of the disease. However, no current 
anti-inflammatory treatments significantly modify the chronic 
inflammatory response or the decline of lung function.
Inhaled glucocorticoids
Although both inhaled and oral glucocorticoids (GCs) are 
effective at controlling inflammatory lung diseases such as 
asthma, their effectiveness is substantially less in COPD; 
therefore, their contribution to the management of stable 
COPD is limited.3,21 Results published from the TOwards 
a Revolution in COPD Health (TORCH) study of patients 
with COPD, with a FEV1 of ,60%, indicated that regular 
use of inhaled GCs may decrease the rate of decline of lung 
function.22 However, the majority of studies have concluded 
that the use of regular inhaled GCs has no impact on the 
long-term progressive decline in FEV1.23–26
Regular treatment with inhaled GCs may reduce the 
frequency of exacerbations of the disease in patients with 
severe (GOLD stage III) and very severe (GOLD stage IV) 
COPD.27–29 Regular inhaled GCs may also reduce dyspnea 
and thereby improve health status.30 In addition, withdrawal 
from inhaled GC treatment can lead to increased rates of 
exacerbations in some patients.31 However, treatment with 
inhaled GCs increases the risk of pneumonia and does not 
reduce the overall mortality.32–34 Therefore, although the 
majority of studies show that inhaled GCs have no impact 
on the progression of the decline of lung function, there 
is evidence that patients with more advanced (GOLD 
stage III or IV) COPD and repeated exacerbations may 
derive some benefit. A number of studies have also shown 
that a combination of long-acting β
2
-agonists (LABAs) and 
inhaled GCs is more effective than either treatment alone 
in reducing exacerbation frequency, improving lung func-
tion, and improving health status.29,30,32,35–38 Results from the 
TORCH study also indicated that a combination therapy of 
LABA and inhaled GC may reduce the rate of decline of lung 
function.22 However, similar to the effects of inhaled GC 
therapy alone, a combination therapy of LABAs and inhaled 
GCs also increases the likelihood of pneumonia and has no 
significant effect on overall mortality.32
Oral GCs
An early study suggested that short-term GC effects can pre-
dict long-term effects of GCs on FEV1; therefore, short-term 
use of oral GCs (2 weeks) could be recommended to assess 
if a patient was likely to benefit from long-term use of either 
inhaled or oral GC therapy.39 However, other recent studies 
indicate that short-term use of oral GCs is a poor predictor 
of long-term response to inhaled GCs.3,26,40 Consequently, 
GOLD guidelines do not recommend undertaking a thera-
peutic trial with oral GCs in patients with stage II (moderate), 
stage III (severe), or stage IV (very severe) COPD who have 
a poor response to an inhaled bronchodilator.3 The short-term 
response to oral course of prednisolone in terms of increased 
airway caliber and improved health-related quality of life can 
be predicted by the presence of sputum eosinophilia.41,42
Oral GCs provide benefit in the treatment of COPD exac-
erbations with a significant reduction in treatment failure and 
the need for additional medical treatment and shorter hospital 
stay.43 However, the benefits of oral GCs in the treatment 
of stable COPD are less evident and convincing given the 
minimal improvements in lung function and the long-term 
side effects of oral GC therapy.44 Therefore, although inhaled 
GCs do have some benefits in the treatment of COPD, par-
ticularly in advanced disease, their benefits are limited; both 
inhaled and oral GC therapies provide more benefit in acute 
exacerbations: the former prevents the exacerbation and the 
latter reverses it. However, the modest beneficial effect of 
inhaled GCs on the frequency of exacerbations has been 
questioned.45–47
GC insensitivity in COPD
The limited effectiveness of GC treatment in COPD com-
pared with other inflammatory lung conditions such as asthma 
has led to the concept that the inflammation in the lung of 
patients with COPD is relatively GC insensitive.21 In addition 
to having no impact on the decline of lung function, inhaled 
GCs have little effect on the numbers of inflammatory cell or 
on the release of proinflammatory mediators in the lungs of 
patients with COPD.48–50 This is reflected ex vivo where GCs 
fail to repress the release of proinflammatory mediators from 
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alveolar macrophages obtained from the bronchoalveolar 
lavage from patients with COPD.51
Development of GC insensitivity  
in COPD
Cellular mechanisms
The molecular mechanisms that contribute to the develop-
ment of a relative GC-insensitive inflammatory response in 
COPD remain unclear. First, there is an inherent variation in 
GC responsiveness between different cell types and tissues.52 
This may relate to the expression of the dominant negative 
glucocorticoid receptor (GR)β isoform, whose expression 
correlates with effective GC function in particular cells or 
tissues.52,53 However, the majority of the cells that make up 
the lung and the infiltrating inflammatory cells in COPD 
are largely responsive to GCs. In addition, other inflamma-
tory conditions involving many of these cell types are well 
controlled. It is therefore unlikely that an intrinsic relative 
GC unresponsiveness of a particular cell type or of the lung 
itself can fully account for the reduction of GC insensitivity 
seen in COPD.
One exception to this is neutrophils, where neutrophillic 
inflammation is relatively unresponsive to GC-mediated 
immunosuppression compared with other cell type predomi-
nant inflammation.45,54,55 Neutrophils are not only present in 
stable COPD but are the predominant infiltrating inflam-
matory cells in exacerbations of the disease, which are also 
controlled to a lesser extent by GCs.45 Some studies have 
suggested that this may be due to a relatively high expres-
sion of the dominant negative GRβ isoform.53 However, 
other studies have found low expression of GRβ; therefore, 
this concept is controversial, and the exact mechanisms 
behind the reduced effectiveness of GCs on neutrophilic 
inflammation remains unclear.56 It is also unclear whether 
the GC insensitivity during exacerbations is an extension of 
the existing GC insensitivity of stable COPD or if there is an 
additional unresponsiveness mediated by the acute elevation 
in neutrophils during the exacerbation.
The levels of GRβ expression have been assessed in 
COPD, but although the expression of GRα is reduced, 
there is no apparent change in the expression of GRβ.55,57 
It is  therefore feasible that a higher level of GRβ to GRα 
ratio in the lung or inflammatory cells in patients with 
COPD may impair GRα function enough to contributing to 
GC  insensitivity. However, with very few studies  assessing 
the relative expressions of GRα and GRβ in COPD and 
 importantly, any functional impact by an elevation in the 
ration of GRβ, it is difficult to assign a role for GRβ in 
the development of GC insensitivity with any confidence. 
Impairment of GRα translocation contributes to reduced 
GC responsiveness in some diseases, such as in a subset of 
patients with multiple sclerosis where an elevation of expres-
sion of heat shock protein 90 (Hsp90) results in increased 
sequestration of GRα to the cytosol.58 However, although 
there is evidence for an elevation of Hsp90 expression in 
COPD, and in some assays, oxidant stress can impair GRα 
translocation in vitro, currently, there is a lack of any compel-
ling in vivo or translational evidence of a role for impaired 
GRα translocation in COPD GC responsiveness.59,60
Genetics
A number of studies have linked genetic mutations with the 
development of GC insensitivity.52 In patients with asthma, 
11 genes have now been identified, which may discriminate 
between relative GC-insensitive and GC – sensitive patients 
with asthma, suggesting that there may be a genetic factor 
in the development of relatively GC-insensitive asthma.61 
A direct link between genetic mutations and the develop-
ment of relative GC insensitivity in COPD has not been 
established. However, there is evidence that genetic suscep-
tibility is likely to play a role in the development of COPD. 
Studies investigating the antioxidant capacity of the lungs 
of patients with COPD and smokers suggest that subjects 
that develop COPD have a reduced capacity to elevate their 
antioxidant defenses, which may, in part, account for the 
development of COPD in a subset of smokers (∼20%) rather 
than all smokers.62–64 Interestingly, the 213Gly variant of the 
antioxidant extracellular superoxide dismutase 3 (SOD3), 
which affects approximately 2% of the population, increases 
the plasma SOD3 levels 10-fold and has been associated with 
a protection in smokers to the consequent development of 
COPD.63,65 Furthermore, given the likely central role for oxi-
dant stress in the development of GC insensitivity (discussed 
in the following section), the reduced antioxidant capacity is 
also likely to contribute to the development of a relative GC 
insensitivity in COPD.
Oxidative stress
As the innate or helper T cell type 1 (T
H
1) inflammatory 
response is well documented as responding well to GCs, 
the enhanced and relatively GC-insensitive inflammatory 
cell present in the lungs of patients with COPD is likely to 
incorporate an underlying factor. One prominent theory is 
that an elevation in the oxidant burden in the lungs (termed 
“oxidative stress”) plays a central role in both the enhance-
ment of the inflammatory response and the development of 
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a relative GC insensitivity.1,66 This concept is supported by 
experimental and mechanistic evidence and is also in align-
ment with other proposed mechanisms including direct dis-
ruption of GRα corepressor activity and alteration of kinase 
signaling, discussed below.
The elevation in the oxidant burden in the lungs of patients 
with COPD may be derived both from exogenous sources, 
such as pollution and cigarette smoke, and  endogenous 
sources, such as respiratory burst of proinflammatory cells, 
such as macrophages and neutrophils. Physiologically, 
 oxidants and the redox state of the cell are an integral part 
of cellular signaling and function including that of GRα.67,68 
However, a significant elevation in the oxidants can over-
come both intracellular and extracellular antioxidant defenses 
leading to significant alterations in signaling pathways and 
protein function.69 The role of exogenous oxidative stress 
derived from cigarette smoke is highlighted by its induction 
of reduced GC insensitivity in experimental models and the 
development of relative GC insensitivity in mild or moderate 
asthma patients who smoke.1,55,70,71
Oxidant stress: HDAC  
and corepressor function
A central factor in both an oxidant-mediated enhancement 
of inflammatory responses and development of relative GC 
insensitivity may be facilitated by a direct alteration in the 
acetylation–deacetylation balance of the core histone pro-
teins.72,73 A central part of GRα function is the recruitment 
of corepressor complexes containing histone deacetylases 
(HDACs), which remove acetyl groups from the NH-terminal 
tails of core histone proteins.73–75 These acetyl groups on 
the histone tails confer a “relaxed” transcriptionally open 
structure to the promoter region of the genes, and their 
removal results in reassociation of the DNA around the core 
histones and gene silencing.73,74,76 In vitro studies using small 
interfering RNA and overexpression models have shown 
that HDAC-2 is the key in the functional mechanism of 
GC-mediated or GRα-mediated histone deacetylation and 
gene repression.77
Acutely, oxidative stress reduces HDAC-2 activity with 
a reduction in HDAC-2 protein expression seen with more 
chronic oxidant exposures in in vitro and in vivo models.71,78,79 
This reduction in HDAC-2 activity and expression is strongly 
associated with oxidant-mediated covalent modifications, 
including hyperphosphorylation, nitration, and carbonyla-
tion, which impair protein activity and enhance proteasomal 
degradation.72,73,78–83 These modifications are mediated by 
reactive oxygen, including reactive carbonyls and reactive 
nitrogen species, and by kinase signaling pathways activated 
by oxidant stress.72,73,83 Although the exact mechanisms and 
pathways that regulate these modifications remain unclear, 
recent work has suggested that oxidants modulate HDAC-2 
phosphorylation and subsequent ubiquitination followed 
by proteasomal degradation through a protein kinase 
CK2α-dependant mechanism.84,85
The acetylation – deacetylation balance of histone is a 
highly regulated process and central in the control of gene 
transcription.74 Therefore, this oxidant-mediated loss of 
HDAC-2 activity and resulting imbalance in histone acety-
lation status are likely to contribute to the enhanced inflam-
matory responses in this disease. In agreement with this, 
HDAC-2 activity and expression are reduced in the peripheral 
lungs of patients with COPD, which correlate with disease 
severity.86 Furthermore, as HDAC-2 activity is  fundamental 
for functional GRα transrepression of proinflammatory 
genes, a reduction in its activity and expression is lightly to 
impair GC function and thereby contributes to a reduction 
in GC responsiveness (Figure 1). Similarly, in models where 
HDAC-2 activity is compromised, GC function is reduced, 
and restoration or protection of HDAC-2 activity is correlated 
with a restoration in GC sensitivity.55,87 Therefore, there is 
strong evidence that the reduction in HDAC-2 activity and 
expression seen in patients with COPD is likely to be an 
important factor in the mechanisms of the relative GC insen-
sitivity in this disease. In addition, as there is a reduction in 
expression of other HDACs in COPD, including HDAC-3, 
5, and 8, it must also be considered that the alteration in the 
expression and/or activity of other HDACs may also play 
a role in the impairment of GC function.86 Cigarette smoke 
exposure results in a reduction of HDAC-1, 2, and 3 in the 
macrophage cell line, Mono Mac 6 cells, associated with 
elevated tyrosine nitration and aldehyde adduct formation.88 
However, the roles of these HDACs in the lung and inflam-
matory cells involved in COPD are poorly understood, and 
studies are needed to clarify their roles in GR function and 
in disease.
Kinase signaling
Kinase signaling is integral to the orchestration of the 
 inflammatory response.89 However, some of these kinase 
pathways are elevated in COPD and may also play a 
role in the development of GC insensitivity in the disease. 
The expression of p38 mitogen-activated protein kinase 
(MAPK) is elevated in the peripheral lungs and alveolar 
 macrophages in patients with mild or moderate COPD 
compared with smokers.90 This study also suggested 
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an inverse correlation between the activation of p38 
MAPK and the reduction in FEV1 and FEV1/FVC.90 An 
 elevation of p38 MAPK may be responsible for an increase 
in  phosphorylation of GRα in a manner that results in a 
 reduction of its ligand-binding ability.91 A negative feedback 
mechanisms used by GCs to regulate the inhibitory effect of 
p38 MAPK on GRα in an induction of MAPK phosphatase-1 
(MKP-1) expression, which reduced p38 MAPK activity by 
 dephosphorylation (REF). A study looking at patients with 
severe asthma vs nonsevere asthma found a reduction in the 
 dexamethasone- induced expression (messenger RNA) of 
MKP-1 and  elevation in p38 activity in patients with severe 
asthma compared with patients with nonsevere asthma.92 
However, no studies have looked at the GC-mediated induc-
tion of MKP-1 in COPD, and consequently no links have yet 
been made between the expression, activity, or signaling of 
MKP-1 and the reduction in GC responsiveness in COPD, 
although the potential is clearly explained.
There is also increasing evidence that a plethora of other 
kinases and signaling pathways, including glycogen synthase 
kinase-3β, extracellular signal-regulated kinase-1/2, and 
c-Jun N-terminal kinase, can directly regulate the activity 
of GRα through phosphorylation and thereafter may also 
influence its gene specificity.93,94
Oxidant stress also activates various kinase pathways, 
including the phosphoinositide 3-kinase (PI3K)/Akt path-
way through selective activation of the PI3Kδ isoform 
(Figure 1).95,96 Our recent study has shown that the activation 
of both PI3Kδ and Akt is elevated in macrophages from the 
peripheral lungs of patients with COPD.96 Specific inhibi-
tion of PI3Kδ/Akt signaling pathway restores and protects 
both HDAC-2 activity and GC function in oxidant-mediated 
GC-insensitive models.55 Similarly, selective inhibition of 
PI3Kδ/Akt pathway restores the ability of GCs to repress 
inflammatory mediator expression in patients with COPD 
comparable to smokers with normal lung function.96 
Cigarette smoke/pollution
Inflammatory cell respiratory burst
Oxidative stress
+
+
Increased PI3Kδ
signalling
Corepressor
complex
Corepressor
complex
Elevated proinflammatory
gene expression
Antioxidant gene expression
Genetic susceptibility: Impaired
antioxidant defence capacity
Nrf2
Oxidants
Antioxidants
GRα
p50
p65
GRα
HDAC-2
HDAC-2
Figure 1 Simplified diagrammatic representation of the mechanisms involved in an oxidant-mediated relative reduction of GC sensitivity. Oxidative stress generated by both 
exogenous and endogenous sources can directly (nitration and aldehyde adduct formation) and indirectly (PI3Kδ/Akt signaling) impair key transcriptional repressor proteins 
utilizing the GRα including HDAC-2, thus preventing GC-mediated repression of proinflammatory mediators. If the antioxidant defense response is impaired, this oxidant 
imbalance results in elevated inflammatory mediator expression, which GC is unable to repress.
Abbreviations: GC, glucocorticoid; PI3K, phosphoinositide 3-kinase; GR, glucocorticoid receptor; HDAC, histone deacetylase; Nrf2, NF-e2-related factor 2 (a major 
regulator of antioxidant gene expression).
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However, although the mechanism by which inhibition 
on PI3Kδ protects GC function appears to be mediated 
through the protection of HDAC-2 activity, it is also likely 
to include modulation of other corepressors, such as Mi-2 
and mSin3a.55,97 The mechanism by which PI3Kδ affects 
HDAC-2 activity and GRα function appears to involve 
oxidant-mediated covalent modifications, including tyrosine 
nitration and hyperphosphorylation induced by the oxidative 
stress.55 However, the mechanisms and pathways that elicited 
downstream of PI3Kδ/Akt signaling during oxidant stress, 
which facilitates the modification of HDAC-2 and expression 
of other corepressors, remain unclear.
Strategies for overcoming GC 
insensitivity in COPD
Restoration of GC function
GCs provide an effective treatment for the control of both 
acute and chronic inflammation in many diseases. Their 
delivery, side effects, and drug–drug interactions are all well 
characterized; therefore, the ability to restore the function 
of GC in COPD is a favorable strategy. The methylxanthine 
theophylline has been shown to provide a GC “sparing” effect 
when given at a low concentration with GCs.98 A low dose of 
theophylline may also improve the anti-inflammatory action 
of GC in an exacerbation of COPD.99 However, the exact 
mechanism of this GC “sparing” action is unclear. Theophyl-
line is often described as a phosphodiesterase (PDE) inhibi-
tor but is also known to have many “off-target” interactions 
including gene regulation.100 Importantly, the concentrations 
that can achieve this GC sparing are below the concentration 
at which it targets PDE. This is further complicated by an 
interesting observation that the binding profile of theophyl-
line is significantly different in cells that have been exposed 
to oxidative stress and is therefore likely to be different in 
patients with COPD and those with their higher oxidant 
burden in lung.100,101 Although the exact direct molecular 
targets of theophylline that confer this GC sparing or enhanc-
ing activity remain unresolved, the downstream mechanism 
involves the restoration of HDAC activity.87,102,103
In addition to theophylline, the curcumin, a polypheno-
lic natural compound, has also demonstrated an ability to 
restore GC function in vitro.104,105 Similar to theophylline, the 
curucmin-mediated restoration of GC function is proposed 
to work through a protection of HDAC-2 expression and 
activity.79 However, as with theophylline, curcumin has a 
seemingly wide and relatively nonspecific action at a range 
of concentrations including activation and repression of sev-
eral kinases and transcription factors. Although functionally 
it has been documented as antioxidant, anti-inflammatory, 
and GC protective, the precise molecular targets for these 
specific actions may be difficult to elucidate, and further 
studies into the precise molecular effectors of its actions 
are required.106
Selective inhibition of PI3Kδ also restores the  ability 
of GCs to repress inflammatory mediator expression, 
which appears to be through protection and/or restoration 
of HDAC-2 activity.55 This similarity between the reported 
mechanisms may indicate that theophylline may be medi-
ated its action through inhibition of the PI3Kδ pathway, but 
although theophylline does inhibit various PI3K isoforms 
at high concentrations, a direct link at a low concentration 
in oxidant-stressed cells has yet to be made.100 The PI3Kδ 
and γ isoforms are also relatively leukocyte specific and are 
central in the orchestration of both the innate and the adap-
tive immune responses, including neutrophil recruitment, 
high-affinity IgE receptor (FcεRI) signaling, and chemokine 
signaling.107–112 Selective PI3Kδ/γ inhibitors have received 
intense interest from the pharmaceutical industry and are 
being developed as anti-inflammatory drugs, particularly 
for allergic disease. Therefore, with selective PI3K isoform 
inhibitors currently under development, the targeting of 
PI3Kδ may be preferable to theophylline whose mechanism 
remains unclear and has no additional anti-inflammatory 
effect itself (Figure 2).
Alternative anti-inflammatory agents
Alternative anti-inflammatory targets have been proposed 
for COPD. TNF-α is a central mediator in the inflammatory 
response seen in the lungs of patients with COPD.7 However, 
a trial with the anti-TNF-α antibody infliximab determined 
that there was no benefit in moderate to severe COPD, and 
this was associated with severe adverse events, particularly 
cancer and lung infections.113 Selective p38 MAPKα inhibi-
tors are potent at suppressing the release of proinflammatory 
mediators in vitro including those closely associated with 
COPD, such as TNF-α and CXCL8.114,115 Selective inhibi-
tion of p38 MAPKα also suppresses oxidant-mediated 
lung inflammation in mice where GCs are not effective, 
indicating that the functional anti-inflammatory properties 
of p38 MAPK inhibitors are not adversely affected by oxi-
dant stress.116,117 The expression of p38 MAPK is elevated 
in the lungs of patients with COPD, and the selective 
inhibitors reduce the expression of inflammatory markers 
in the blood of patients with COPD.118 This suggests that 
selective targeting of p38 MAPK in COPD may provide a 
potentially effective alternative therapeutic strategy to GCs 
International Journal of Chronic Obstructive Pulmonary Disease 2010:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
304
Marwick and Chung
(Figure 2), particularly that it may also enhance the effect 
of any  concomitant GC therapy. However, p38 MAPKα 
is important in many cell functions, and one major hurdle 
facing the development of selective p38 MAPKα inhibitors 
appears to be cytotoxicity.119
Proresolving strategies
A significant driving force behind an enhanced and persis-
tent inflammation may be an inability of the inflammation 
to resolve and thereby self-regulate. This is likely to be an 
integral factor in COPD where even after the removal of the 
exogenous driving force (predominantly, cigarette smoke), 
the inflammatory response continues. This impairment of 
inflammatory resolution may be particularly important in 
the context of GC treatment in COPD.
Although GCs are not effective at repressing neutrophilic 
inflammation, studies have shown that GCs can significantly 
impair the rate of constitutive apoptosis of neutrophils.120 
This constitutive cell death is an important “safety” feature 
of neutrophil function, which prevents a prolonged release 
of toxic and damaging agents, such as superoxide and 
neutrophil elastase, which may damage otherwise healthy 
tissue, thereby perpetuating the inflammatory response.121 
Controlled cell death termed “apoptosis” is a key feature of 
neutrophil cell death, as this prevents the release of the toxic 
and inflammatory contents of the dead cell and also targets 
the cell for phagocytosis and clearance by macrophages.121–123 
The nonphlogistic clearance of apoptotic neutrophils is also 
considered a central feature in inflammatory resolution, as 
it triggers a switch in the phenotype of the macrophages 
from proinflammatory to proresolving with the release 
of proresolving mediators, such as prostaglandin E
2
 and 
IL-10.121,124–126
Macrophage phagocytosis is impaired in COPD, which 
may be due to the effect of cigarette smoke, and there-
fore, the rate of the clearance of apoptotic neutrophils 
is likely to be reduced.127,128 If GC treatment of patients 
with COPD reflects what is seen in in vitro assays with a 
delay in neutrophil apoptosis, then the neutrophil may not 
only be living longer and releasing more inflammatory 
Figure 2 Possible therapeutic strategies for alternative effective anti-inflammatory drugs or for the additional restoration of GC function for an oxidant-mediated reduction 
in GC sensitivity. An effective antioxidant would combat one of the major contributing factors to the chronic and relatively GC unresponsive inflammation in COPD. 
Current therapies such as theophylline may be able to restore the effectiveness of GCs, thus allowing GC to be more effective in COPD. Oxidant-driven alterations in kinase 
signaling are likely to contribute to the impaired GRα function in COPD and selective targeting of these pathways, such as PI3Kδ and p38 MAPK, which could also restore 
the effectives of GC in COPD. In addition, alternative anti-inflammatory inhibitors, such as PI3Kδ/γ or p38 MAPK, may also provide effective alternative or combinatorial 
anti-inflammatory strategy to GCs in the oxidant-driven inflammation in COPD.
Abbreviations: GC, glucocorticoid; COPD, chronic obstructive pulmonary disease; GR, glucocorticoid receptor; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated 
protein kinase; JNK, c-Jun N-terminal kinase; GSK, glycogen synthase kinase; eRK, extracellular signal-regulated kinase; HDAC, histone deacetylase.
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agents but also be fueling the destruction of the lung and 
 inflammatory response by the release of its cellular contents 
through  necrosis due to its defective clearance by resident 
 macrophages. A few studies have looked into inflammatory 
resolution in COPD, and there is little direct information on 
the impact of GCs; however, this area may prove to be useful 
in finding potentially effective and novel anti-inflammatory 
drugs for COPD.
Interestingly, in addition to their role in initiation of 
both innate and adaptive immune responses and a potential 
role in the restoration of GC function, PI3Ks may also play 
an important role in the resolution of inflammation. The 
resolution or allergen-induced eosinophilic inflammation is 
enhanced by inhibition of PI3K by a mechanism involving 
blockade of Akt activation and enhanced cell apoptosis.129 
Studies using both transgenic mice and selective inhibitors 
have demonstrated that PI3Kβ is required for functional Fcγ 
receptor-mediated macrophage phagocytosis.130  Therefore, 
in addition to their anti-inflammatory action, selective 
PI3K inhibitors may also promote inflammatory resolution 
and thereby may provide an additional therapeutic benefit. 
A range of other small-molecule inhibitors that target the 
rate of neutrophil apoptosis has also been developed. These 
include inhibitors of cyclin-dependant kinases such as 
 roscovitine, which have recently been shown to promote 
neutophil apoptosis and inflammatory resolution in vivo.123 
Therefore, selective inhibitors that promote neutrophil cell 
death may also provide a therapeutic inflammatory prore-
solution strategy, although the effectiveness of this in the 
presence of defective clearance must be investigated. Another 
approach to promoting the resolution of inflammation is the 
therapeutic use of molecules that mimic the actions of potent 
endogenous proresolving mediators such as the lipid mediator 
resolvin E1.131 Such therapies are currently under develop-
ment, including the resolvin E1 mimetic (Resolvyx™); 
however, their potential therapeutic application in COPD 
has yet to be investigated.
Summary
GCs are not effective at controlling the chronic inflammatory 
response in COPD. This persistent and abnormal inflamma-
tion in the lung increases as the disease progresses. To date, 
there are no effective treatments to control this persistent 
inflammatory response and the associated decline of lung 
function of COPD. This is largely due to a lack of under-
standing the nature of the inflammatory response in COPD 
and the impact of key underlying factors such as oxidative 
stress on this inflammatory response.
It is clear that an effective anti-inflammatory therapy is 
likely to play a central role in the effective management of the 
disease in the future. It is therefore critical that we understand 
the mechanism of the abnormal inflammatory response in 
COPD, including the defective ability of GC-activated GRα 
to repress proinflammatory responses. Therapeutic targeting 
is likely to involve the oxidant-mediated alterations in kinase 
signaling and protein function, such as p38 MAPK, PI3Kδ, 
and GRα corepressors including HDAC-2. A more detailed 
elucidation of these pathways is needed before selected tar-
gets can be identified. In addition, agents that can restore GC 
sensitivity could be developed through an understanding of 
oxidant stress effects on GRs and signaling pathways. Some 
of these agents may also confer effective anti-inflammatory 
effects in COPD themselves. Finally, given the lack of 
successful anti-inflammatory drugs for COPD, a combina-
tion therapy directed in tandem against other aspects of the 
inflammatory response such as antioxidants and proresolving 
therapies may prove to be more effective at controlling the 
inflammation and thereafter halting the decline of both lung 
function and disease progression.
Acknowledgments
This study was supported by the UK Medical Research 
Council and Medical Research Scotland (Marwick) and by 
the UK Medical Research Council and the Wellcome Trust 
grants (Chung).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflam-
mation, immunity, and tissue repair and destruction. Eur Respir J. 
2008;31(6):1334–1356.
2. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway 
obstruction in chronic obstructive pulmonary disease. N Engl J Med. 
2004;350(26):2645–2653.
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagno-
sis, management, and prevention of chronic obstructive pulmonary 
disease: GOLD executive summary. Am J Respir Crit Care Med. 
2007;176(6):532–555.
4. Mannino DM, Buist AS. Global burden of COPD: risk factors, preva-
lence, and future trends. Lancet. 2007;370(9589):765–773.
5. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in 
the prevalence of COPD (the BOLD Study): a population-based preva-
lence study. Lancet. 2007;370(9589):741–750.
6. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary 
disease. Nat Rev Immunol. 2008;8(3):183–192.
7. Barnes PJ. The cytokine network in asthma and chronic obstructive 
pulmonary disease. J Clin Invest. 2008;118(11):3546–3556.
8. World Health Organisation. WHO Statistical Information System 
(WHOSIS). Available from: http://www.who.int/whosis/whostat/2008/
en/index.html. Published 2008 Jan 1.
International Journal of Chronic Obstructive Pulmonary Disease 2010:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
306
Marwick and Chung
 9. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, 
Wedzicha JA. Relationship between bacterial colonisation and the 
frequency, character, and severity of COPD exacerbations. Thorax. 
2002;57(9):759–764.
 10. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest. 
2000;117(5 Suppl 1):286S–291S.
 11. Kim WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG. 
Centrilobular and panlobular emphysema in smokers. Two distinct 
morphologic and functional entities. Am Rev Respir Dis. 1991;144(6): 
1385–1390.
 12. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive 
pulmonary disease. Lancet. 2004;364(9435):709–721.
 13. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic 
obstructive pulmonary disease. N Engl J Med. 2009;360(23): 
2445–2454.
 14. Gosman MME, Willemse BWM, Jansen DF, et al. Increased 
number of B-cells in bronchial biopsies in COPD. Eur Respir J. 
2006;27(1):60–64.
 15. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco 
smoking-induced emphysema. Nat Med. 2007;13(5):567–569.
 16. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies 
in patients with chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med. 2008;177(2):156–163.
 17. Koethe SM, Kuhnmuench JR, Becker CG. Neutrophil priming by 
cigarette smoke condensate and a tobacco anti-idiotypic antibody. Am 
J Pathol. 2000;157(5):1735–1743.
 18. Stringer KA, Tobias M, O’Neill HC, Franklin CC. Cigarette smoke 
extract-induced suppression of caspase-3-like activity impairs human 
neutrophil phagocytosis. Am J Physiol Lung Cell Mol Physiol. 
2007;292(6):L1572–L1579.
 19. Berenson C, Garlipp M, Grove L, Maloney J, Sethi S. Impaired phago-
cytosis of nontypeable Haemophilus influenzae by human alveolar 
macrophages in chronic obstructive pulmonary disease. J Infect Dis. 
2006;194(10):1375–1384.
 20. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective  macrophage 
phagocytosis of bacteria in COPD. Eur Respir J. 2010;35(5): 
1039–1047.
 21. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory 
diseases. Lancet. 2009;373(9678):1905–1917.
 22. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy 
on rate of decline of lung function in chronic obstructive pulmonary 
disease: results from the TORCH study. Am J Respir Crit Care Med. 
2008;178(4):332–338.
 23. Vestbo Jo, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-
term effect of inhaled budesonide in mild and moderate chronic 
obstructive pulmonary disease: a randomised controlled trial. Lancet. 
1999;353(9167):1819–1823.
 24. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment 
with inhaled budesonide in persons with mild chronic obstruc-
tive pulmonary disease who continue smoking. N Engl J Med. 
1999;340(25):1948–1953.
 25. The Lung Health Study Research Group. Effect of inhaled triamcinolone 
on the decline in pulmonary function in chronic obstructive pulmonary 
disease. N Engl J Med. 2000;343(26):1902–1909.
 26. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, 
Maslen TK. Randomised, double blind, placebo controlled study of 
 fluticasone propionate in patients with moderate to severe chronic 
obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 
320(7245):1297–1303.
 27. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing 
exacerbations on deterioration of health status in COPD. Eur Respir J. 
2004;23(5):698–702.
 28. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and 
the effect of fluticasone propionate on chronic obstructive pulmonary 
disease exacerbations. Eur Respir J. 2003;21(1):68–73.
 29. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and 
fluticasone in the treatment of chronic obstructive pulmonary disease: 
a randomised controlled trial. Lancet. 2003;361(9356):449–456.
 30. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone 
propionate and salmeterol combination delivered via the Diskus device 
in the treatment of chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med. 2002;166(8):1084–1091.
 31. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, 
van Herwaarden C. Effect of discontinuation of inhaled corticosteroids 
in patients with chronic obstructive pulmonary disease: the COPE study. 
Am J Respir Crit Care Med. 2002;166(10):1358–1363.
 32. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone 
propionate and survival in chronic obstructive pulmonary disease. 
N Engl J Med. 2007;356(8):775–789.
 33. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. 
Inhaled corticosteroids in patients with stable chronic obstructive 
pulmonary disease: a systematic review and meta-analysis. JAMA. 
2008;300(20):2407–2416.
 34. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids 
and the risk of pneumonia in chronic obstructive pulmonary disease: a 
meta-analysis. Arch Intern Med. 2009;169(3):219–229.
 35. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of 
 budesonide/formoterol in the management of chronic obstructive 
pulmonary disease. Eur Respir J. 2003;21(1):74–81.
 36. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety 
of fluticasone propionate (250 microg)/salmeterol (50 microg) 
combined in the Diskus inhaler for the treatment of COPD. Chest. 
2003;124(3):834–843.
 37. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, 
 Olsson H. Maintenance therapy with budesonide and formoterol in 
chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6): 
912–919.
 38. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/
fluticasone propionate versus salmeterol on exacerbations in severe 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
2007;175(2):144–149.
 39. Callahan CM, Dittus RS, Katz B. Oral corticosteroid therapy for patients 
with stable chronic obstructive pulmonary disease. A meta-analysis. 
Ann Intern Med. 1991;114(3):216–223.
 40. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Predni-
solone response in patients with chronic obstructive pulmonary disease: 
results from the ISOLDE study. Thorax. 2003;58(8):654–658.
 41. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and 
the short term response to inhaled mometasone in chronic obstructive 
pulmonary disease. Thorax. 2005;60(3):193–198.
 42. Pizzichini E, Pizzichini M, Gibson P, et al. Sputum eosinophilia predicts 
benefit from prednisone in smokers with chronic obstructive bronchitis. 
Am J Respir Crit Care Med. 1998;158(5):1511–1517.
 43. Walters J, Gibson P, Wood-Baker R, Hannay M, Walters E. Systemic 
corticosteroids for acute exacerbations of chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev. 2009;1:CD001288.
 44. Wood-Baker R, Walters J, Haydn Walters E. Systemic corticosteroids 
in chronic obstructive pulmonary disease: an overview of Cochrane 
systematic reviews. Respir Med. 2007;101(3):371–377.
 45. Barnes PJ. New molecular targets for the treatment of neutrophilic 
diseases. J Allergy Clin Immunol. 2007;119(5):1055–1062.
 46. Yang I, Fong K, Sim E, Black PN, Lasserson TJ. Inhaled corticosteroids 
for stable chronic obstructive disease. Cochrane Database Syst Rev. 
2007;2:CD002991.
 47. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues 
in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927–933.
 48. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, 
Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and 
proteases in induced sputum in chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med, 1999;160(5):1635–1639.
International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
307
Glucocorticoid insensitivity in chronic obstructive pulmonary disease
 49. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled 
and oral glucocorticoids on inflammatory indices in asthma and COPD. 
Am J Respir Crit Care Med. 1997;155(2):542–548.
50. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, 
 Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on 
airway inflammation in COPD: a randomised controlled trial. Thorax. 
2007;62(11):938–943.
 51. Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by 
 dexamethasone of cytokine release by alveolar macrophages from 
patients with chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med. 2003;167(1):24–31.
 52. Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family 
affair. Trends Endocrinol Metab. 2008;19(9):331–339.
 53. Strickland I, Kisich K, Hauk PJ, et al. High constitutive glucocorticoid 
receptor beta in human neutrophils enables them to reduce their spon-
taneous rate of cell death in response to corticosteroids. J Exp Med. 
2001;193(5):585–594.
 54. Ito K, Herbert C, Siegle JS, et al. Steroid-resistant neutrophilic inflam-
mation in a mouse model of an acute exacerbation of asthma. Am J 
Respir Cell Mol Biol. 2008;39(5):543–50.
 55. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of 
PI3Kdelta restores glucocorticoid function in smoking-induced air-
way inflammation in mice. Am J Respir Crit Care Med. 2009;179(7): 
542–548.
 56. Pujols L, Mullol J, Roca-Ferrer J, et al. Expression of glucocorticoid 
receptor alpha- and beta-isoforms in human cells and tissues. Am J 
Physiol Cell Physiol. 2002;283(4):C1324–C1331.
 57. Korn SH, Thunnissen FBJM, Wesseling GJ, Arends J-W, Wouters EFM. 
Glucocorticoid receptor mRNA levels in bronchial epithelial cells 
of patients with COPD: influence of glucocorticoids. Respir Med. 
1998;92(9):1102–1109.
 58. Matysiak M, Makosa B, Walczak A, Selmaj K. Patients with multiple 
sclerosis resisted to glucocorticoid therapy: abnormal expression of 
heat-shock protein 90 in glucocorticoid receptor complex. Mult Scler. 
2008;14(7):919–926.
 59. Hacker S, Lambers C, Heotzenecker K, et al. Elevated HSP27, 
HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: 
markers for immune activation and tissue destruction. Clin Lab. 
2009;55(1–2):31–40.
 60. Okamoto K, Tanaka H, Ogawa H, et al. Redox-dependent regula-
tion of nuclear import of the glucocorticoid receptor. J Biol Chem. 
1999;274(15):10363–10371.
 61. Hakonarson H, Bjornsdottir US, Halapi E, et al. Profiling of genes 
expressed in peripheral blood mononuclear cells predicts gluco-
corticoid sensitivity in asthma patients. Proc Nat Acad Sci U S A. 
2005;102(41):14789–14794.
 62. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-analyses 
on suspected chronic obstructive pulmonary disease genes: a summary 
of 20 Years’ Research. Am J Respir Crit Care Med. 2009;180(7): 
618–631.
 63. Young RP, Hopkins R, Black PN, et al. Functional variants of antioxidant 
genes in smokers with COPD and in those with normal lung function. 
Thorax. 2006;61(5):394–399.
 64. Mak JC, Ho SP, Yu WC, et al. Polymorphisms and functional activity 
in superoxide dismutase and catalase genes in smokers with COPD. 
Eur Respir J. 2007;30(4):684–690.
 65. Juul K, Tybjaerg-Hansen A, Marklund S, Lange P, Nordestgaard BG. 
Genetically increased antioxidative protection and decreased chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 
173(8):858–864.
 66. Ciencewicki J, Trivedi S, Kleeberger SR. Oxidants and the pathogenesis 
of lung diseases. J Allergy Clin Immunol. 2008;122(3):456–468.
 67. Hwang NR, Yim S, Kim YM, et al. Oxidative modifications of 
 glyceraldehyde-3-phosphate dehydrogenase play a key role in its 
multiple cellular functions. Biochem J. 2009;423(2):253–264.
 68. Kitagawa H, Yamaoka I, Akimoto C, et al. A reduction state potenti-
ates the glucocorticoid response through receptor protein stabilization. 
Genes Cells. 2007;12(11):1281–1287.
 69. Wright VP, Reiser PJ, Clanton TL. Redox modulation of global phos-
phatase activity and protein phosphorylation in intact skeletal muscle. 
J Physiol. 2009;587(23):5767–5781.
 70. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, 
Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smok-
ers versus non-smokers with mild asthma. Thorax. 2005;60(4):282–287.
 71. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette 
smoking reduces histone deacetylase 2 expression, enhances cytokine 
expression, and inhibits glucocorticoid actions in alveolar macrophages. 
FASEB J. 2001;15(6):1110–1112.
 72. Rahman I, Marwick J, Kirkham P. Redox modulation of chromatin 
remodeling: impact on histone acetylation and deacetylation, NF-
kappaB and pro-inflammatory gene expression. Biochem Pharmacol. 
2004;68(6):1255–1267.
 73. Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and 
steroid resistance in asthma and COPD: pharmacological manipula-
tion of HDAC-2 as a therapeutic strategy. Expert Opin Ther Targets. 
2007;11(6):745–755.
 74. Li B, Carey M, Workman JL. The role of chromatin during transcrip-
tion. Cell. 2007;128(4):707–719.
 75. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflam-
mation and immunity. Nat Rev Immunol. 2006;6(1):44–55.
 76. Choi JK, Howe LJ. Histone acetylation: truth of consequences? Biochem 
Cell Biol. 2009;87(1):139–150.
 77. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 
2-mediated deacetylation of the glucocorticoid receptor enables NF-
kappaB suppression. J Exp Med. 2006;203(1):7–13.
 78. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smoke alters 
chromatin remodeling and induces proinflammatory genes in rat lungs. 
Am J Respir Cell Mol Biol. 2004;31(6):633–642.
 79. Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin restores cor-
ticosteroid function in monocytes exposed to oxidants by maintaining 
HDAC2. Am J Respir Cell Mol Biol. 2008;39(3):312–323.
 80. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative 
stress reduces histone deacetylase 2 activity and enhances IL-8 gene 
expression: role of tyrosine nitration. Biochem Biophys Res Commun. 
2004;315(1):240–245.
 81. Osoata GO, Yamamura S, Ito M, et al. Nitration of distinct tyrosine 
residues causes inactivation of histone deacetylase 2. Biochem Biophys 
Res Commun. 2009;384(3):366–371.
 82. Galasinski SC, Resing KA, Goodrich JA, Ahn NG. Phosphatase inhibition 
leads to histone deacetylases 1 and 2 phosphorylation and disruption of 
corepressor interactions. J Biol Chem. 2002;277(22):19618–19626.
 83. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung 
inflammation in COPD. Eur Respir J. 2006;28(1):219–242.
 84. Adenuga D, Yao H, March TH, Seagrave J, Rahman I. Histone deacety-
lase 2 is phosphorylated, ubiquitinated, and degraded by cigarette 
smoke. Am J Respir Cell Mol Biol. 2009;40(4):464–473.
 85. Adenuga D, Rahman I. Protein kinase CK2-mediated phosphorylation 
of HDAC2 regulates co-repressor formation, deacetylase activity and 
acetylation of HDAC2 by cigarette smoke and aldehydes. Arch Biochem 
Biophys. 2010;498(1):62–73.
 86. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase 
activity in chronic obstructive pulmonary disease. N Engl J Med. 
2005;352(19):1967–1976.
 87. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. 
Theophylline restores histone deacetylase activity and steroid responses 
in COPD macrophages. J Exp Med. 2004;200(5):689–695.
 88. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces 
proinflammatory cytokine release by activation of NF-kappaB and 
posttranslational modifications of histone deacetylase in macrophages. 
Am J Physiol Lung Cell Mol Physiol. 2006;291(1):L46–L57.
International Journal of Chronic Obstructive Pulmonary Disease 2010:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
308
Marwick and Chung
 89. Adcock IM, Chung KF, Caramori G, Ito K. Kinase inhibitors and 
airway inflammation. Euro J Pharmacol. 2006;533(1–3):118–132.
 90. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK 
in COPD. Eur Respir J. 2008;31(1):62–69.
 91. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. 
p38 Mitogen-activated protein kinase-induced  glucocorticoid receptor 
phosphorylation reduces its activity: role in steroid-insensitive asthma. 
J Allergy Clin Immunol. 2002;109(4):649–657.
 92. Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insen-
sitivity of alveolar macrophages in severe asthma compared with 
non-severe asthma. Thorax. 2008;63(9):784–790.
 93. Galliher-Beckley AJ, Cidlowski JA. Emerging roles of glucocorticoid 
receptor phosphorylation in modulating glucocorticoid hormone action 
in health and disease. IUBMB Life. 2009;61:979–986.
 94. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA. 
 Glycogen synthase kinase 3beta-mediated serine phosphorylation of 
the human glucocorticoid receptor redirects gene expression profiles. 
Mol Cell Biol. 2008;28(24):7309–7322.
 95. Barthel A, Klotz LO. Phosphoinositide 3-kinase signaling in the 
cellular response to oxidative stress. Biol Chem. 2005;386(3): 
207–216.
 96. Marwick JA, Caramori G, Casolari P, et al. A role for phosphoinositol 
3-kinase delta in the impairment of glucocorticoid responsivness in 
patients with chronic obstructive pulmonary disease. J Allergy Clin 
Immunol. 2010;125(5):1146–1153.
 97. Marwick JA, Stevenson CS, Chung KF, Adcock IM, Kirkham PA. 
Cigarette smoke exposure alters mSin3a and Mi-2alpha/beta expres-
sion; implications in the control of pro-inflammatory gene transcription 
and glucocorticoid function. J Inflamm. In press 2010.
 98. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, 
Barnes PJ. A comparison of low-dose inhaled budesonide plus 
 theophylline and high-dose inhaled budesonide for moderate asthma. 
N Engl J Med. 1997;337(20):1412–1418.
 99. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances 
the anti-inflammatory effects of steroids during exacerbations of 
COPD. Thorax. 2009;64(5):424–429.
 100. Marwick JA, Wallis G, Meja K, et al. Oxidative stress modulates 
theophylline effects on steroid responsiveness. Biochem Biophys Res 
Commun. 2008;377(3):797–802.
 101. Cusack BJ, Dawson GW, Mercer GD, Vestal RE. Cigarette smoking 
and theophylline metabolism: effects of cimetidine. Clin Pharm Ther. 
1985;37(3):330–336.
 102. Ito K, Lim S, Caramori G, et al. A molecular mechanism of 
action of theophylline: induction of histone deacetylase activity to 
decrease inflammatory gene expression. Proc Nat Acad Sci U S A. 
2002;99(13):8921–8926.
 103. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. 
Treatment effects of low-dose theophylline combined with an inhaled 
corticosteroid in COPD. Chest. 2010;137(6):1338–1344.
 104. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation 
and redox signaling by dietary polyphenols. Biochem Pharmacol. 
2006;72(11):1439–1452.
 105. Rahman I. Dietary polyphenols mediated regulation of oxidative 
stress and chromatin remodeling in inflammation. Nutr Rev. 2008; 
66(Suppl 1):S42–S45.
 106. Bengmark S, Mesa M, Gil A. Plant-derived health: the effects of 
turmeric and curcuminoids. Nut Hosp. 2009;24:273–281.
 107. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kγ in thymocyte 
development, T cell activation, and neutrophil migration. Science. 
2000;287(5455):1040–1046.
 108. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G protein-
coupled phosphoinositide 3-kinase γ in Inflammation. Science. 
2000;287(5455):1049–1053.
 109. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell anti-
gen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 
2002;297(5583):1031–1034.
 110. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte  development, 
differentiation and activation. Nat Rev Immunol. 2003;3(4): 
317–330.
 111. Condliffe AM, Davidson K, Anderson KE, et al. Sequential acti-
vation of class IB and class IA PI3K is important for the primed 
respiratory burst of human but not murine neutrophils. Blood. 
2005;106(4):1432–1440.
 112. Puri KD, Doggett TA, Douangpanya J, et al. Mechanisms and impli-
cations of phosphoinositide 3-kinase delta in promoting neutrophil 
trafficking into inflamed tissue. Blood. 2004;103(9):3448–3456.
 113. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of 
 infliximab in moderate to severe chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 2007;175(9):926–934.
 114. Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 
mitogen-activated protein kinase inhibitors on cytokine release from 
human macrophages. Br J Pharmacol. 2006;149(4):393–404.
 115. Tudhope SJ, Finney-Hayward TK, Nicholson AG, et al.  Different 
 mitogen-activated protein kinase-dependent cytokine responses in 
cells of the monocyte lineage. J Pharmacol Exp Ther. 2008;324(1): 
306–312.
 116. Medicherla S, Fitzgerald MF, Spicer D, et al. p38alpha selective 
mitogen-activated protein kinase inhibitor SD-282 reduces inflam-
mation in a subchronic model of tobacco smoke-induced airway 
inflammation. J Pharmacol Exp Ther. 2008;324(3):921–929.
 117. Williams AS, Issa R, Durham A, et al. Role of p38 mitogen-activated 
protein kinase in ozone-induced airway hyperresponsiveness and 
inflammation. Eur J Pharmacol. 2008;600(1–3):117–122.
 118. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A randomized, 
placebo-controlled study of the effects of the p38 MAPK inhibitor 
SB-681323 on blood biomarkers of inflammation in COPD patients. 
J Clin Pharmacol. 2010;50(1):94–100.
 119. Dambach DM. Potential adverse effects associated with inhi-
bition of p38alpha/beta MAP kinases. Curr Top Med Chem. 
2005;5(10):929–939.
 120. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of 
glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic 
granulocytes. J Immunol. 1996;156(11):4422–4428.
 121. Serhan CN, Savill J. Resolution of inflammation: the beginning pro-
grams the end. Nat Immunol. 2005;6(12):1191–1197.
 122. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, 
Haslett C. Macrophage phagocytosis of aging neutrophils in 
 inflammation. Programmed cell death in the neutrophil leads to its 
recognition by macrophages. J Clin Invest. 1989;83(3):865–875.
 123. Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase 
inhibitors enhance the resolution of inflammation by promoting inflam-
matory cell apoptosis. Nat Med. 2006;12(9):1056–1064.
 124. Michlewska S, Dransfield I, Megson IL, Rossi AG. Macrophage 
phagocytosis of apoptotic neutrophils is critically regulated by the 
opposing actions of pro-inflammatory and anti-inflammatory agents: 
key role for TNF-α. FASEB J. 2009;23(3):844–854.
 125. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, 
Henson PM. Macrophages that have ingested apoptotic cells in vitro 
inhibit proinflammatory cytokine production through autocrine/
paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin 
Invest. 1998;101(4):890–898.
 126. Voll  RE, Her rmann M, Roth EA, Stach C, Kalden JR, 
 Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 
1997;390(6658):350–351.
 127. Kirkham PA, Spooner G, Rahman I, Rossi AG. Macrophage phago-
cytosis of apoptotic neutrophils is compromised by matrix proteins 
modified by cigarette smoke and lipid peroxidation products. Biochem 
Biophys Res Commun. 2004;318(1):32–37.
 128. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. 
Smoking alters alveolar macrophage recognition and phagocytic 
ability: implications in chronic obstructive pulmonary disease. Am J 
Respir Cell Mol Biol. 2007;37(6):748–755.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
309
Glucocorticoid insensitivity in chronic obstructive pulmonary disease
 129. Pinho V, Souza DG, Barsante MM, et al. Phosphoinositide-3 kinases 
critically regulate the recruitment and survival of eosinophils in vivo: 
importance for the resolution of allergic inflammation. J Leukoc Biol. 
2005;77(5):800–810.
 130. Leverrier Y, Okkenhaug K, Sawyer C, Bilancio A, Vanhaesebroeck B, 
Ridley AJ. Class I phosphoinositide 3-kinase p110beta is required 
for apoptotic cell and Fcgamma receptor-mediated phagocytosis by 
macrophages. J Biol Chem. 2003;278(40):38437–38442.
 131. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and 
 protectin D1 activate inflammation-resolution programmes. Nature. 
2007;447(7146):869–874.
